The British Association for the Study of the Liver is a multi-disciplinary society with around 900 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions.
The British Association for the Study of the Liver aims to disseminate research findings and clinical expertise, to promote opportunities for collaboration in liver research, to provide a voice that can advise and interact with the media and advises policymakers.
For 20 years The PBC Foundation has been supporting people diagnosed and living with Primary Biliary Cholangitis. After BASL 2016 on 9–11 Sept PBC members and supporters were involved in the 'three peaks in three days challenge (Scafell, Snowdon, Ben Nevis).
PBC Foundation ‘three peaks challenge’ - Robert Mitchell-Thain, Dimitar Tonev & Andy Bailey, amongst others took part.
PBC Foundation ‘three peaks challenge’ - a similar event will follow BASL 2017 and we hope that BASL members will take part next year.
Find out more
Find out more about the work of our committee sub-groups and forums by clicking the logos below. These include The British Viral Hepatitis Group, British Association for the Study of the Liver Nurse Forum and the British Liver Transplant Group.
The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.
British Association for the Study of the Liver Nurse Forum is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.
The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development.
BASL is a multi-disciplinary society with around 900 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions. Your Annual subscription is used to organise the Annual Meeting held each September.
Members of BASL receive the following benefits:
- discounted registration rates for the annual meeting and other relevant meetings
- eligibility for the BASL Travel Awards (for members below status of Senior Lecturer or Consultant to allow presentation of high-quality UK liver research at International meetings, including the American Association for the Study of Liver Disease)
- eligibility for the prestigious Dame Sheila Sherlock Award (to an emerging researcher in the field of liver disease, for members below status of Senior Lecturer or consultant). Applications are usually submitted to the BASL Committee three months prior to the annual meeting - details are announced.
Click here to find out more about joining us.
This webinar is for anyone who wants to understand the challenges to reduce liver disease.
By joining the webinar participants will:
Explore the variations in liver disease risk factors and outcomes
Learn about PHEs programmes of action on liver disease
Look at time series data to identify where variation has improved, stayed the same or got worse
Explore the stories behind the data
Have an opportunity to ask a question to the national team
The webinar* will be held on Thursday 26 January 2016 - 2:00pm and 3:00pm.
Registration is FREE for this event and if you have already expressed an interest in attending this webinar, then we will have your details on our system. If you have not registered, please do so > Here:
If you have any questions about registration, please contact Kerry.email@example.com .
*Webinar details will be sent out prior to the session
The Gilead UK and Ireland Fellowship Programme 2017 will open soon for grant applications in the therapy area of viral hepatitis. The aim of the programme is to support local innovation and best practice in patient care.
The programme invites applications from healthcare or allied professionals that:
1. Innovative local integrated initiatives to evaluate effectiveness of non-hospital based HCV treatment service models
2. Novel HCV care pathways using partnership models demonstrating measurable improvements in patient engagement
Projects which fall outside of this scope but which will add clinical value or which investigate an area of unmet need within viral hepatitis can also be submitted and will be reviewed for their merit.
The Gilead UK and Ireland Fellowship Programme started in 2009, and since its inception has supported over 150 projects in the areas of HIV, Viral Hepatitis, Respiratory, Invasive Fungal Disease and Oncology.
You can apply for a viral hepatitis grant by clicking > here .
Due to the current post holder having being elected as Chair of the British Viral Hepatitis Group (BVHG) the BVHG are seeking nominations / expressions of interest for the post of Secretary.
The British Viral Hepatitis Group aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.
BVHG Committee Secretary
The BVHG Secretary is elected by the BASL / BVHG membership to serve for a period of up to three year’s and may be re-elected once. The Secretary is responsible for running the administrative tasks pertaining to his/her function and will work closely with the BASL Secretariat, which is appointed by the BASL Governing Board.
The BVHG is commissioned by the BASL Governing Board to:
• a) promote research and the exchange of scientific information concerning viral hepatitis;
• b) foster multicentre scientific studies pertaining to viral hepatitis within the UK;
• c) promote education of physicians, surgeons, clinical nurse specialists and scientists with regard to viral hepatitides and their management;
• d) Promote interaction between clinical disciplines to promote good care of patients and foster research and clinical trials.
Candidates wishing to be considered for election will require one BASL member to propose them and a second BASL member to confirm their suitability for the role in writing.
Please email Judy Hawksworth at the BASL Secretariat Judith@execbs.com with your nominations by 17:00 on Friday 6th January 2017. Following this time candidate statements will be requested and voting will take place if necessary.
If you require any further information about this role please contact Dr Ahmed Elsharkawy at Ahmed.ElSharkawy@uhb.nhs.uk or contact Judy Hawksworth as above.
Direct-acting antiviral (DAA)-based therapies are effective and well-tolerated for HCV patients with stage four to five chronic kidney disease, a meta-analysis of published studies shows.
Reviewers at the Second Hospital of Shandong University in China found 11 studies involving a total of 264 patients. The pooled SVR12 rate was 93.2% for the total population, 89.4% for sofosbuvir-based therapies, and 94.7% for non-sofosbuvir-based therapies. For HCV genotype 1 patients, the pooled SVR12 rate was 93.1%.
The pooled incidence of serious adverse events was 12.1%, and the pooled discontinuation rate because of adverse events or serious adverse events was 2.2%.
Efficacy and safety of DAA-based antiviral therapies for HCV patients with stage 4-5 chronic kidney disease: a meta-analysis. Li T, Qu Y, Guo Y et al. Liver Int. 2016 Dec 10 [Epub ahead of print]
A large observational study in the USA confirmed haemophilia per se does not have a specific influence on transplant outcomes in HCV patients, but that HIV infection increases the risk of mortality in both haemophilic (H) and non-haemophilic (NH) patients.
Researchers identified 2,502 HCV-positive liver transplant candidates from eight US university-based transplant centres between 2004 and 2010, including 144 HIV-positive and 2,358 HIV-negative; 36 H and 2,466 NH; 1,213 transplanted and 1,289 not transplanted patients.
In univariate analysis, 90-day pre-transplant mortality was associated with higher baseline MELD (hazard ratio 1.15), lower baseline platelet count (hazard ratio 1.11 per 25k/µL), and having HIV/HCV-positive haemophilia.
In multivariate analysis, pre-transplant mortality was associated with higher MELD and was significantly greater in HIV-positive than HIV- groups, but did not differ between HIV-positive H and NH (hazard ratio 1.7). Among HIV/HCV-positive, post-transplant mortality was similar between H and NH, despite lower CD4 in H.
Haemophilia liver transplantation observational study (HOTS). Ragni MV, Humar A, Stock PG et al. Liver Transpl. 2016 Dec 9 [Epub ahead of print]
A significant number of HCV patients develop a major depressive episode (MDE) during interferon-alpha (IFN-α) based immunotherapy, and several mechanisms may be involved.
Authors of a new literature review found eight unique references which met their inclusion criteria, and which involved 826 people with HCV (37.3% females). The overall MDE incidence rate was 34.8%, with follow-up ranging between four and 48 weeks. The methodological quality varied across selected studies. It was found that Interleukin-6, salivary cortisol, arachidonic acid/eicosapentaenoicacid plus ocosahexaenoic acid ratio, and genetic polymorphisms may present variations which are linked to a predisposition to INF-α-induced depression.
However, a meta-analysis could not be performed because of the diverse biological mechanisms investigated and the lack of replicated evidence. The reviewers, therefore, concluded the mechanisms involved in IFN-α-induced depression in humans remained unclear.
Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: a critical systematic review. Machado MO, Oriolo G, Bortolato B et al. J Affect Disord. 2016 Nov 27; 209:235-245 [Epub ahead of print]
The third report of the Lancet Commission into Liver Disease in the UK was published online on Friday 16th December 2016.
Visit the Lancet website to read the report > click here.
Responding to the release on 14 December 2016 of the 2015 Health Survey for England, Professor Sir Ian Gilmore, chair of the Alcohol Health Alliance UK, said:
"We welcome the continuing downward trend in children aged 8-15 being exposed to alcohol.
However, the figures for adults are worrying as they reveal that in 2015, 31% of men and 16% of women in England drank more than the current low risk weekly guideline of 14 units a week spread out across 4-5 days.
Drinking above the low risk guideline places people at increased risk of illnesses like heart disease, liver disease and cancer.
The most recent UK guidelines on low-risk drinking, and the reasons behind them, have simply not been communicated adequately. The government needs to ensure the public are aware of the current drinking guidelines, as well as the harms associated with alcohol. The public have the right to know, so they can make informed choices about their drinking.
The government should communicate the risks in two ways.
Firstly, the government should develop mass media campaigns outlining the risks. These could include TV and radio advertisements, social media campaigns, and messages on public transport.
Second, the government should introduce mandatory labelling of all alcoholic products, containing clear and legible health information about the harms associated with drinking."
The 4th National Gastrointestinal Nursing Conference is taking place at the America Square Conference Centre, London.
The National Gastrointestinal Nursing Conference promotes the many facets of gastrointestinal nursing and will be of interest to:
• IBD nurse specialists
• Clinical nurse specialists (stoma care, hepatology, IBD, gastroenterology, endoscopy)
• Stoma care nurses
• Nurse endoscopists
• Liver nurses
• Colorectal nurses
• Upper GI nurses
• Lower GI nurses
• Enhanced recovery nurses
You can find out more information and view the programme here > Download Gastrointestinal Nursing Conference Programme 2017.pdf .
To book your place click > HERE.
If you have any questions contact Jennifer on tel: 020 7501 6786.
The Turkish Association for the Study of the Liver (TASL) and The American Association for the Study of Liver Diseases (AASLD) Joint Meeting will be held on March 3-4, 2017, in İstanbul Turkey.
The TASL and AASLD meeting promises to be an outstanding congress with an innovative scientific program and world-renowned invited scientists in the field of acute and chronic viral hepatitis.
To find out more information visit the meeting website by clicking > here.
The next meeting of the British Viral Hepatitis Group (BVHG) will take place on Friday10th March 2017 at The Hallam Conference Centre London.
The BVHG aims to improve the management and study of patients with chronic viral liver disease. The group brings together UK hepatologists, gastroenterologists, infectious disease physicians as well as virologists and epidemiologists with an interest in viral diseases of the liver.
Viral Hepatitis: Can we eradicate Hepatitis C in the UK by 2030?
09:00 - 09:30 Registration
09:30 - 09:40 Welcome and introduction: Dr Ahmed Elsharkawy / Dr Will Gelson
ODNs: achievements and future challenges
09:40 – 09.55 North of England Update
09.55 – 10.10 Midlands and the East Update – Dr Will Gelson – Cambridge University Hospitals
10:10 - 10:25 South of England Update
10:25 - 10:40 An Update from Wales
10:40 – 10.55 An Update from Scotland
11:00 - 11.30 Coffee
11:30 - 12:15 Keynote Speaker – Is eradication of Hepatitis C in England achievable?
12:15 – 13.00 Symposium sponsored by Gilead
13.00 – 13:45 Lunch
Diagnosing the Undiagnosed
13:45 – 14:05 What role can the RCGP and its new focus on liver disease play in achieving Hepatitis C eradication?
14:05 – 14:25 Empowering Primary Care – the HepCAT project. Design and preliminary findings.
Engaging the Disengaged
14:25 – 14.45 Drug service outreach – how to make it work for you?
14.45 – 15.05 Lessons learnt from setting up a prison in reach service. Dr Chris Corbett – Royal Wolverhampton Hospitals
15.05 – 15.15 Panel discussion
15:15 – 15:40 Coffee
15:40 – 16:10 The Hepatitis C Coalition Framework
16:10 – 16:30 Summary and close – Dr Ahmed Elsharkawy - University Hospital Birmingham
Premier sponsors - Gilead, Abbvie
Key sponsors - MSD
To book click > here or use the link below.
The Liver Disease in Primary Care course takes place on Tuesday 21st - Wednesday 22nd March 2017 at the University of Birmingham.
This two day course aims to provide theoretical and practical knowledge of liver diseases and how to manage them in primary care.
Further information can be found here – Download Birmingham Liver Disease Course Flyer March 2017.pdf
Or contact Grace Nikobari at firstname.lastname@example.org .
BASL are endorsing the 3rd Nottingham Postgraduate Course for the Gastroenterology Specialty Certificate Examination.
This year the course takes place on 23rd-24th March at the Queen's Medical Centre, Nottingham.
The HCC-UK meeting in 2017 takes place on Thursday 30th March at Hilton Newcastle/Gateshead.
HCC-UK comprises professionals of multidisciplines interested in improving outcomes for the increasing numbers of patients with hepatocellular carcinoma (HCC).
The meeting will focus on:
• an update of surgical treatments for early stage disease
• locoregional and medical therapies for those with more advanced disease
• current best practice clinical management across early and more advanced stage disease.
Case presentations, within a multidisciplinary environment, will play a key part of all sessions.
This meeting is accredited for 6 hours CPD and should appeal to all members of multidisciplinary teams, as well as trainees in gastroenterology and hepatology.
To view the programme and to find out how to register click > HERE.
APASL is one of the leading associations based on investigation and treatment of liver diseases that upholds the standards and profession, research and create improved treatment methods for millions of liver patients particularly in the entire Asia Pacific Region.
Meeting Venue: Hotel Okura JR Huis Ten Bosch Nagasaki, Japan
For more information please visit the APASL STC 2017 Nagasaki website > HERE.
Important dates can be found below:
- January 31, 2017 - Abstract Submission Deadline
- February 14, 2017 - Early Bird Registration Deadline
- March 10, 2017 - Pre-Registration will Close
The International Liver Congress™ 2017 (ILC 2017) is the 52nd annual meeting of the European Association for the Study of the Liver (EASL), the Home of Hepatology.
Join the international liver community at the RAI Congress Centre, Amsterdam,The Netherlands from 19 to 23 April 2017.
In the digital communication era, ILC 2017 still provides a unique opportunity for clinicians and scientists from all over the world to meet not only to discuss clinical innovation and research challenges but also to interact socially, network and develop future collaborations. Although EASL is a professional medical organisation based in Europe, ILC has attracted over the past years, an increasing number of participants from 120 countries thanks to an exciting programme mixing state-of the art education and cutting edge science.
Registration and Abstract submissions are now open. For further information about the meeting click > HERE.
Early Registration Fees end 31 December 2016.
Join BASL Ward Membership Today - £100 per annum for up to 5 members per ward.
Benefits include; access to Nurse e-learning toolkits, reduced fees at BASL Events including the Nurses Day at the Annual Meeting.
To find out how to apply click here
Click here to view the BASL Events Newsletter - August
Click here to view the BASL Newsletter - October
Click here to view the infohep.org Newsletter - December 2016
Click here to view the Alcohol Health Alliance Newsletter - December 2016.
The BASL Nurse Toolkits were developed following conversations with nurse specialists. These and a later email survey identified training needs to help nurses meet the liver nurse competencies. To access the Learning Toolkits sign in as a BASL Member and click on Manage Account